Key takeaways
Raloxifene (Evista) and tamoxifen (Nolvadex) are both selective estrogen receptor modulators (SERMs) used to lower the risk of breast cancer, but they have some key differences. Raloxifene is specifically for postmenopausal women and can also be used to treat osteoporosis, while tamoxifen can be used by both premenopausal and postmenopausal women. Tamoxifen also treats various stages of hormone receptor-positive (HR+) breast cancer. Raloxifene is taken once daily and is not associated with uterine cancer, whereas tamoxifen is also taken once daily but can increase the risk of uterine cancer. Common side effects of raloxifene include hot flashes and joint pain, while tamoxifen can cause swelling in the arms and legs, nausea, and vaginal discharge. Both medications carry a risk of blood clots, but tamoxifen also has a risk of cataracts and liver problems. Tamoxifen and Evistat are both available as a lower-cost generic.
